verified99%+ Verified Purity
local_shippingFast EU Delivery (through resellers)
Myotrope
Homechevron_rightAll Peptideschevron_rightRetatrutide Injection Pen
Retatrutide Injection Pen
verified_user

Safety data sheet

Standardized safety protocols and material specifications for professional use.

analytics

Certificate of Analysis

Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-retatrutide-injection-pen-60mg

Official Product Data Sheet

Retatrutide Injection Pen (60mg)

High >98% Purity

Vial Contents
60 mg Retatrutide (3 mL pre-filled injection pen)
Includes
Ready-to-use high-capacity multi-dose pen — no mixing required
Form
Pre-filled high-capacity pen
Purity
≥98%, third-party verified
Sequence
Triple Agonist (GLP-1/GIP/Glucagon)
Molecular Formula
See chemical properties
Molecular Mass
≈4731 g/mol
CAS No.
2381089-83-2
Solubility
Concentration: 20 mg/mL | Per click: 1 unit ≈ 200 mcg
Storage
Refrigerate at 2–8 °C. Protect from light. Do not freeze.

Authorized Resellers

Available through our trusted partners

12
verifiedVerified

123peptide.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new
DE
verifiedVerified

Depeptidenwinkel.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new
View all authorized resellersshopping_cart
swipe_rightSwipe to see all tabs

Scientific Background

Retatrutide is an advanced triple GLP-1/GIP/glucagon receptor agonist with Phase 3 data showing up to 28.7% body weight reduction. The 60 mg pen at 20 mg/mL (200 mcg per click) delivers the maximum per-pen economy — ideal for extended high-dose protocols at 3–8 mg/week without frequent pen changes.

Intended Research Use

  • Extended high-dose triple-receptor activation research
  • Long-cycle obesity protocols (10–20+ weeks at maintenance dose)
  • Maximum per-pen economy for institutional or multi-subject research
  • Dose-escalation from 2–8 mg/week

menu_bookScientific Publications

article

N Engl J Med (2023)

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/37366315/

article

Eli Lilly Press Release (2025)

Lilly TRIUMPH-4 Phase 3: Up to 28.7% weight loss (average 71.2 lbs)

open_in_newhttps://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average

warning

FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.

Myotrope

Possible stacks with other peptides

Synergistic combinations for enhanced research outcomes

Retatrutide pairs well with complementary metabolic and regenerative peptides.

GLOW Blend 70mg

GLOW Blend 70mg (70mg vial)

arrow_forward

myo-glow-blend-70mg

Tissue repair, skin quality, and reduced GI side-effects alongside Retatrutide's powerful metabolic action.

Cagrilintide 10mg

Cagrilintide 10mg (10mg vial)

arrow_forward

myo-cagrilintide-10mg

Complementary amylin-pathway satiety for additive appetite suppression.

AOD-9604 5mg

AOD-9604 5mg (5mg vial)

arrow_forward

myo-hgh-fragment-aod-9604-5mg

Targeted lipolysis in stubborn fat zones alongside systemic metabolic benefits.

schedule

Cycling Note: Titrate every 4 weeks. This format supports continuous 20+ week protocols without pen changes.

Also Available

Retatrutide 10mg
Vial

Retatrutide

10mg

Retatrutide 15mg
Vial

Retatrutide

15mg

Retatrutide 20mg
Vial

Retatrutide

20mg

Retatrutide Injection Pen 10mg
Pen

Retatrutide Injection Pen

10mg

Retatrutide Injection Pen 15mg
Pen

Retatrutide Injection Pen

15mg

Retatrutide Injection Pen 20mg
Pen

Retatrutide Injection Pen

20mg

Retatrutide Injection Pen 30mg
Pen

Retatrutide Injection Pen

30mg